193 related articles for article (PubMed ID: 25285661)
1. Structural basis for resistance to diverse classes of NAMPT inhibitors.
Wang W; Elkins K; Oh A; Ho YC; Wu J; Li H; Xiao Y; Kwong M; Coons M; Brillantes B; Cheng E; Crocker L; Dragovich PS; Sampath D; Zheng X; Bair KW; O'Brien T; Belmont LD
PLoS One; 2014; 9(10):e109366. PubMed ID: 25285661
[TBL] [Abstract][Full Text] [Related]
2. Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase.
Olesen UH; Petersen JG; Garten A; Kiess W; Yoshino J; Imai S; Christensen MK; Fristrup P; Thougaard AV; Björkling F; Jensen PB; Nielsen SJ; Sehested M
BMC Cancer; 2010 Dec; 10():677. PubMed ID: 21144000
[TBL] [Abstract][Full Text] [Related]
3. Identification of novel resistance mechanisms to NAMPT inhibition via the de novo NAD
Guo J; Lam LT; Longenecker KL; Bui MH; Idler KB; Glaser KB; Wilsbacher JL; Tse C; Pappano WN; Huang TH
Biochem Biophys Res Commun; 2017 Sep; 491(3):681-686. PubMed ID: 28756225
[TBL] [Abstract][Full Text] [Related]
4. Structural and biochemical analyses of the catalysis and potency impact of inhibitor phosphoribosylation by human nicotinamide phosphoribosyltransferase.
Oh A; Ho YC; Zak M; Liu Y; Chen X; Yuen PW; Zheng X; Liu Y; Dragovich PS; Wang W
Chembiochem; 2014 May; 15(8):1121-30. PubMed ID: 24797455
[TBL] [Abstract][Full Text] [Related]
5. SAR and characterization of non-substrate isoindoline urea inhibitors of nicotinamide phosphoribosyltransferase (NAMPT).
Curtin ML; Heyman HR; Clark RF; Sorensen BK; Doherty GA; Hansen TM; Frey RR; Sarris KA; Aguirre AL; Shrestha A; Tu N; Woller K; Pliushchev MA; Sweis RF; Cheng M; Wilsbacher JL; Kovar PJ; Guo J; Cheng D; Longenecker KL; Raich D; Korepanova AV; Soni NB; Algire MA; Richardson PL; Marin VL; Badagnani I; Vasudevan A; Buchanan FG; Maag D; Chiang GG; Tse C; Michaelides MR
Bioorg Med Chem Lett; 2017 Aug; 27(15):3317-3325. PubMed ID: 28610984
[TBL] [Abstract][Full Text] [Related]
6. Discovery of Novel Inhibitors and Fluorescent Probe Targeting NAMPT.
Wang X; Xu TY; Liu XZ; Zhang SL; Wang P; Li ZY; Guan YF; Wang SN; Dong GQ; Zhuo S; Le YY; Sheng CQ; Miao CY
Sci Rep; 2015 Jul; 5():12657. PubMed ID: 26227784
[TBL] [Abstract][Full Text] [Related]
7. Supplementation of nicotinic acid with NAMPT inhibitors results in loss of in vivo efficacy in NAPRT1-deficient tumor models.
O'Brien T; Oeh J; Xiao Y; Liang X; Vanderbilt A; Qin A; Yang L; Lee LB; Ly J; Cosino E; LaCap JA; Ogasawara A; Williams S; Nannini M; Liederer BM; Jackson P; Dragovich PS; Sampath D
Neoplasia; 2013 Dec; 15(12):1314-29. PubMed ID: 24403854
[TBL] [Abstract][Full Text] [Related]
8. Regulation of the Nampt-mediated NAD salvage pathway and its therapeutic implications in pancreatic cancer.
Ju HQ; Zhuang ZN; Li H; Tian T; Lu YX; Fan XQ; Zhou HJ; Mo HY; Sheng H; Chiao PJ; Xu RH
Cancer Lett; 2016 Aug; 379(1):1-11. PubMed ID: 27233476
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Nicotinamide Phosphoribosyltransferase (NAMPT), an Enzyme Essential for NAD+ Biosynthesis, Leads to Altered Carbohydrate Metabolism in Cancer Cells.
Tan B; Dong S; Shepard RL; Kays L; Roth KD; Geeganage S; Kuo MS; Zhao G
J Biol Chem; 2015 Jun; 290(25):15812-15824. PubMed ID: 25944913
[TBL] [Abstract][Full Text] [Related]
10. Genomic and tumor biological aspects of the anticancer nicotinamide phosphoribosyltransferase inhibitor FK866 in resistant human colorectal cancer cells.
Ogino Y; Sato A; Uchiumi F; Tanuma SI
Genomics; 2019 Dec; 111(6):1889-1895. PubMed ID: 30582964
[TBL] [Abstract][Full Text] [Related]
11. Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition.
Cea M; Cagnetta A; Fulciniti M; Tai YT; Hideshima T; Chauhan D; Roccaro A; Sacco A; Calimeri T; Cottini F; Jakubikova J; Kong SY; Patrone F; Nencioni A; Gobbi M; Richardson P; Munshi N; Anderson KC
Blood; 2012 Oct; 120(17):3519-29. PubMed ID: 22955917
[TBL] [Abstract][Full Text] [Related]
12. Discovery of a novel nicotinamide phosphoribosyl transferase (NAMPT) inhibitor via in silico screening.
Takeuchi M; Niimi T; Masumoto M; Orita M; Yokota H; Yamamoto T
Biol Pharm Bull; 2014; 37(1):31-6. PubMed ID: 24389478
[TBL] [Abstract][Full Text] [Related]
13. Nicotinamide phosphoribosyl transferase regulates cell growth via the Sirt1/P53 signaling pathway and is a prognosis marker in colorectal cancer.
Pan JH; Zhou H; Zhu SB; Huang JL; Zhao XX; Ding H; Qin L; Pan YL
J Cell Physiol; 2019 Apr; 234(4):4385-4395. PubMed ID: 30191976
[TBL] [Abstract][Full Text] [Related]
14. Fragment-based design of 3-aminopyridine-derived amides as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).
Dragovich PS; Zhao G; Baumeister T; Bravo B; Giannetti AM; Ho YC; Hua R; Li G; Liang X; Ma X; O'Brien T; Oh A; Skelton NJ; Wang C; Wang W; Wang Y; Xiao Y; Yuen PW; Zak M; Zhao Q; Zheng X
Bioorg Med Chem Lett; 2014 Feb; 24(3):954-62. PubMed ID: 24433859
[TBL] [Abstract][Full Text] [Related]
15. Application of virtual screening to the discovery of novel nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with potential for the treatment of cancer and axonopathies.
Clark DE; Waszkowycz B; Wong M; Lockey PM; Adalbert R; Gilley J; Clark J; Coleman MP
Bioorg Med Chem Lett; 2016 Jun; 26(12):2920-2926. PubMed ID: 27158141
[TBL] [Abstract][Full Text] [Related]
16. Weak coupling of ATP hydrolysis to the chemical equilibrium of human nicotinamide phosphoribosyltransferase.
Burgos ES; Schramm VL
Biochemistry; 2008 Oct; 47(42):11086-96. PubMed ID: 18823127
[TBL] [Abstract][Full Text] [Related]
17. Nicotinic Acid Phosphoribosyltransferase Regulates Cancer Cell Metabolism, Susceptibility to NAMPT Inhibitors, and DNA Repair.
Piacente F; Caffa I; Ravera S; Sociali G; Passalacqua M; Vellone VG; Becherini P; Reverberi D; Monacelli F; Ballestrero A; Odetti P; Cagnetta A; Cea M; Nahimana A; Duchosal M; Bruzzone S; Nencioni A
Cancer Res; 2017 Jul; 77(14):3857-3869. PubMed ID: 28507103
[TBL] [Abstract][Full Text] [Related]
18. Discovery and characterization of novel small-molecule inhibitors targeting nicotinamide phosphoribosyltransferase.
Xu TY; Zhang SL; Dong GQ; Liu XZ; Wang X; Lv XQ; Qian QJ; Zhang RY; Sheng CQ; Miao CY
Sci Rep; 2015 Jun; 5():10043. PubMed ID: 26040985
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer.
Sampath D; Zabka TS; Misner DL; O'Brien T; Dragovich PS
Pharmacol Ther; 2015 Jul; 151():16-31. PubMed ID: 25709099
[TBL] [Abstract][Full Text] [Related]
20. Identification of amides derived from 1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).
Zheng X; Bair KW; Bauer P; Baumeister T; Bowman KK; Buckmelter AJ; Caligiuri M; Clodfelter KH; Feng Y; Han B; Ho YC; Kley N; Li H; Liang X; Liederer BM; Lin J; Ly J; O'Brien T; Oeh J; Oh A; Reynolds DJ; Sampath D; Sharma G; Skelton N; Smith CC; Tremayne J; Wang L; Wang W; Wang Z; Wu H; Wu J; Xiao Y; Yang G; Yuen PW; Zak M; Dragovich PS
Bioorg Med Chem Lett; 2013 Oct; 23(20):5488-97. PubMed ID: 24021463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
